within Pharmacolibrary.Drugs.ATC.J;

model J01EB04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.85,
    Cl             = 0.024 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 1000 / 1000000,
    adminCount     = 1,
    Vd             = 0.00049,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0021666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Sulfapyridine is a sulfonamide antibacterial drug that was historically used to treat bacterial infections, particularly in the pre-penicillin era. It is a synthetic antimicrobial agent. Its use has largely declined due to the development of more effective and less toxic antibiotics, though it is sometimes still encountered as a metabolite of sulfasalazine, a drug used for rheumatoid arthritis and inflammatory bowel disease.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are reported for healthy adult volunteers following oral administration.</p><h4>References</h4><ol><li><p>Awni, WM, Braeckman, RA, Locke, CS, Dubé, LM, &amp; Granneman, GR (1995). The influence of multiple oral doses of zileuton on the steady-state pharmacokinetics of sulfasalazine and its metabolites, sulfapyridine and N-acetylsulfapyridine. <i>Clinical pharmacokinetics</i> 29 Suppl 2 98–104. DOI:<a href=&quot;https://doi.org/10.2165/00003088-199500292-00014&quot;>10.2165/00003088-199500292-00014</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8620678/&quot;>https://pubmed.ncbi.nlm.nih.gov/8620678</a></p></li><li><p>Bates, TR, Blumenthal, HP, &amp; Pieniaszek, HJ (1977). Salivary excretion and pharmacokinetics of sulfapyridine after sulfasalazine. <i>Clinical pharmacology and therapeutics</i> 22(6) 917–927. DOI:<a href=&quot;https://doi.org/10.1002/cpt1977226917&quot;>10.1002/cpt1977226917</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21768/&quot;>https://pubmed.ncbi.nlm.nih.gov/21768</a></p></li><li><p>Tett, SE (1993). Clinical pharmacokinetics of slow-acting antirheumatic drugs. <i>Clinical pharmacokinetics</i> 25(5) 392–407. DOI:<a href=&quot;https://doi.org/10.2165/00003088-199325050-00005&quot;>10.2165/00003088-199325050-00005</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7904547/&quot;>https://pubmed.ncbi.nlm.nih.gov/7904547</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J01EB04;
